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a b s t r a c t
Psoriasis, as the most common inﬂammatory skin disorder, affects about 2–3% of the world’s
population. Many non-dermatological conditions have been linked with psoriasis, includ-
ing cardiovascular diseases, depression, inﬂammatory bowel disorders, and some cancers,
i.e. lung, colon and kidney cancers. Among systemic factors are endocrine and metabolic
disturbances as well as many drugs. Erythrodermic psoriasis, the most severe form of the
disease, is characterized by diffuse erytrema and scaling, often accompanied by fever, chills,
and malaise.
A 57-year-old Caucasian man was admitted for curative radiation therapy of adeno-
carcinoma of the prostate after 3 months of initial hormonal therapy. The management
comprised the combined androgen blockade (CAB). On admission the patient reported esca-
lation of psoriasis symptoms, which he had been treated for since 2002. Due to a mild course
of the disease he had not required any systemic treatment ever before, even during aggra-
vation periods. The last exacerbation started appearing a month after hormonal therapy
implementation. The cutaneous eruptions, already existing, become larger with new foci
revealing, mainly on upper and lower limbs. During radiotherapy planning, there appeared
a diffuse erythema and scaling onhands and feetwith accompanying pruritis.Wedecided to
start the previously planned radiation therapywhich included theprostate glandwith 1.5 cm
margin andprovided for the total dose of 72Gy in 36 fractions. The irradiationwas conducted
with the four-ﬁeld technique using a megavoltage linear accelerator. During radiotherapy
we photo-documented skin lesions.To our best knowledge hormone therapy (androgen deprivation) of prostate cancer
patients has not been reported as an aggravating factor. Thus, the aim of our work is to
present the case of a prostate cancer patient who experienced psoriasis exacerbation after
implementation of hormonal blockade as a neoadjuvant oncological treatment.
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1. Introduction
Psoriasis, as the most common inﬂammatory skin disor-
der, affects about 2–3% of the world’s population.1 Most
cases represent type 1 psoriasis with the peak of incidence
(often familial) between the age of 20 and 30 years, com-
mon susceptibility alleles at the HLA locus, and often severe
course of the disease.2 Type 2 psoriasis, more typical for
older patients, usually requires local treatment only and does
not show a hereditary nature.3 Lots of non-dermatological
conditions have been linked with psoriasis, including cardio-
vascular diseases, depression, inﬂammatory bowel disorders,
and some cancers, i.e. lung, colon and kidney cancers.2
Plenty of diverse endogenous and exogenous factors have
been recognized to trigger or exacerbate psoriatic signs. Psy-
chogenic stress and bacterial infections are listed as main
inducers,4 but it is known that any local skin trauma may pro-
voke suffering (Koebner’s phenomenon).2,5 Among systemic
factors endocrine and metabolic disturbances (hypocal-
cemia, dyslipidemia, impaired glucose tolerance), as well as
many drugs, including lithium salts, antimalarials, NSAIDs,
ACE-inhibitors, beta-blockers, calcium-blockers, some antibi-
otics and interferons have been proven to initiate the
disease.5,6 There have also been reported anectodal cases
of psoriasis aggravation after digoxin, morphine, anabolic
steroids, progesterone, antidepressants, diuretics, antiepilep-
tics, hypolipidemic agents, growth factors and H2-blockers
administration.3,7 Undoubtedly, many other drugs show a
potential to inﬂuence the disease course and their identiﬁ-
cation could be crucial for maintaining regression of psoriasis
symptoms.
To our best knowledge, hormone therapy (androgen depri-
vation) of prostate cancer patients has not been reported as an
aggravating factor. Thus the aim of our work is to present the
case of a prostate cancer patient who experienced psoriasis
exacerbation after implementation of hormonal blockade as a
neoadjuvant oncological treatment.
2. Case report
A 57-year-old Caucasian man was admitted (July 2008) for
curative radiation therapy of adenocarcinoma of the prostate
after 3 months of initial hormonal therapy. The manage-
ment comprised the combined androgen blockade (CAB)
– luteinizing hormone-releasing hormone (LH-RH) analog
(agonist), given subcutaneously once per 12 weeks Triptore-
lin +anti-androgen Flutamide given orally 3 times per day. The
patient presented T2bN0M0 clinical stage and was assigned
to the low-risk group (PSA 8.64ng/ml, Gleason 4). MRI of the
pelvis (January 2008) revealed the enlarged prostate gland
(4.5 cm×4.0 cm×4.3 cm) with the contrast-enhanced area in
the right lobe of 1.9 cm in diameter, with no radiological
features of the prostate capsule inﬁltration and no lymph
node metastases. On admission the patient reported escala-
tion of psoriasis symptoms, which he had been treated for
since 2002. Due to a mild course of the disease he had not
required any systemic treatment ever before, even during
aggravation periods. The last exacerbation started appearingFig. 1 – Diffuse erythema on the forearm after
hormonotherapy in prostate cancer patient.
a month after hormonal therapy implementation. The cuta-
neous eruptions, already existing, become largerwith new foci
revealing, mainly on upper and lower limbs. During radiother-
apy planning, there appeared a diffuse erythema and scaling
on hands and feet with accompanying pruritis (Figs. 1 and 2).
We observed deterioration of the patient’s general condition,
however, neither fever nor enlarged lymph nodes were found.
There were no abnormalities in laboratory test results, either.
The patient was consulted by a dermatologist and the deci-
sion was made to stop the hormonal therapy immediately as
well as to apply local corticosteroid ointment. The features
of skin inﬂammation disappeared completely in 3 days and
the pruritis decreased considerably. The skin desquamation
remained (Fig. 3). Since the general condition of the patient
also improved (and was estimated as good), we decided to
start the previously planned radiation therapy which included
the prostate gland with 1.5 cm margin and provided for the
total dose of 72Gy in 36 fractions. The irradiation was con-
ducted with the four-ﬁeld technique using a megavoltage (a
15MeV photon beam) linear accelerator. During radiother-
apy we photo-documented skin lesions. Radiation-induced
reaction of the skin was assessed once a week according to
the EORTC classiﬁcation. A special attention was attached to
Fig. 2 – Diffuse erythema on the cruarls after
hormonotherapy in prostate cancer patient.
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the role of androgens.13 However, it has been proven that
androgens protect against autoimmunization development
and show an immunomodulative activity.14,15 In our patient
we cannot exclude other (not yet investigated) psoriasis aggra-
vation mechanisms of hormonal drugs, unrelated to androgen
level modulation.
Analyzing the role of hormones in dermatological symp-
tom exacerbation, we cannot also exclude the impact of stress
hormones in our patient as cancer diagnosis and implemen-
tation of any oncological treatment are undeniably connected
with an intense stress, a factor of a documented impact on
psoriasis course.
Treating a patient with aggravated psoriasis symptoms, we
paid a special attention to possible appearance of the Koeb-
ner’s phenomenon on the irradiated skin area, as reported
by some authors,5,6,16,17 especially for larger fraction doses
exceeding 2.5Gy.5,18 Using the fraction dose of 2Gy, we did
not observe the phenomenon, neither during radiotherapynor
after its completion.
The case presented conﬁrms previous observations that
cancer patients with accompanying psoriasis may be safely
irradiated with low fraction doses. However, a special atten-
tion should be paid to those of them who simultaneously
receive hormonal treatment, especially in the case of an active
phase of psoriasis and multiple skin lesions.
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